Oxaliplatin Fresenius Kabi

Oxaliplatin, the active ingredient in Oxaliplatin Fresenius Kabi, is a platinum compound presented as a sterile solution for intravenous use. It is employed in the treatment of colorectal cancer and other gastrointestinal malignancies in adult patients. GNH USA supplies Oxaliplatin Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

GNH USA supplies Oxaliplatin Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Oxaliplatin is a platinum‑based chemotherapeutic agent used primarily within colorectal cancer treatment pathways.

- Colorectal cancer: enhances tumor response when combined with fluoropyrimidine‑based regimens. - Gastric cancer: contributes to disease control as part of combination chemotherapy. - Pancreatic cancer: used in select protocols to improve progression‑free survival. - Adjuvant therapy: administered after surgical resection to reduce recurrence risk. - Metastatic disease: employed to shrink tumors and alleviate symptoms in advanced stages.

Oxaliplatin may cause a range of adverse reactions, from mild to severe, that require monitoring during therapy.

Common Side Effects: - Nausea and vomiting: frequent gastrointestinal upset during infusion. - Peripheral neuropathy: tingling or numbness in hands and feet, often dose‑related. - Diarrhea: watery stools that may require supportive care. - Fatigue: generalized tiredness affecting daily activities. - Myelosuppression: reduced blood cell counts, increasing infection risk. - Elevated liver enzymes: transient changes in hepatic function tests.

Serious or Rare Side Effects: - Severe hypersensitivity reactions: rash, bronchospasm, or anaphylaxis. - Acute neurotoxicity: sudden onset of muscle cramps or difficulty breathing. - Thrombotic events: blood clot formation in veins or arteries. - Severe myelosuppression: profound neutropenia or thrombocytopenia. - Renal impairment: acute kidney injury requiring monitoring. - Cardiac arrhythmias: irregular heart rhythms observed during infusion.

When handling Oxaliplatin, clinicians should observe specific safety measures and patient monitoring protocols.

- Renal function: assess baseline creatinine and adjust therapy if impairment is present. - Hepatic function: monitor liver enzymes before each cycle. - Neuropathy risk: evaluate pre‑existing peripheral neuropathy and adjust dose as needed. - Hematologic status: perform complete blood counts regularly to detect myelosuppression. - Pregnancy and lactation: avoid use unless benefits outweigh risks; discuss with obstetric specialist. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Oxaliplatin can interact with several concomitant medications, influencing efficacy or toxicity.

Major Interactions (Avoid): - Nephrotoxic agents (e.g., cisplatin, aminoglycosides): increase risk of renal damage. - Highly protein‑bound drugs (e.g., warfarin): may alter plasma concentrations.

Moderate Interactions (Monitor Closely): - Antiemetics (e.g., ondansetron): may affect oxaliplatin clearance. - CYP450 inducers (e.g., rifampicin): potential reduction in drug exposure. - Antioxidants (e.g., vitamin C high doses): could diminish platinum‑DNA binding. - Radiotherapy: concurrent use may enhance neurotoxicity. - NSAIDs: may exacerbate renal toxicity when combined.